While purchasing medicine - It is important that you let us know what other medicine you are using.
This is for preventing unwanted drug interactions.


Want to ask us a professional question ? Call us or Connect VIA Skype





Skype Me™! 
 



 
 
 
 

IFOXAN
Home >> Search Drug By Letter >> Search Drug By Letter: I >> IFOXAN
Search Drug By Letter : A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

IFOXAN
 
 
Package(a):
VIALS: 1 x 500 mg.
Dosage(a):
Adults: Intravenous bolus administration: The usual total dose for each course is 8-10 g / m² equally fractionated as single daily doses over 5 days i.e. 1.6-2.0 g/m²/day, for 5 days. See data sheet. 
Children: Intravenous bolus administration: The usual dose for each course is 8-10 g/m², equally divided as single daily doses over 5 days i.e. 1.6-2.0 g/m²/day, for 5 days.
Prescribing RestrictionsKupah Pharmacy Only Medical Division Approval

Package(b):
VIALS: 1 x 1 G, 2 G.
Dosage(b):
Adults: Intravenous bolus administration: The usual total dose for each course is 8-10 g/m² equally fractionated as single daily doses over 5 days i.e. 1.6-2.0 g/m²/day, for 5 days. See data sheet. 
Children: Intravenous bolus administration: The usual dose for each course is 8-10 g/m², equally divided as single daily doses over 5 days i.e. 1.6-2.0 g/m²/day, for 5 days.
Prescribing Restrictions:  Kupah Pharmacy Only Medical Division Approval


Indications:
Tumor of lung, ovary, cervix, breast, testes, soft tissue sarcoma. Also osteosarcoma, malignant lymphomas, carcinoma of pancreas, head and neck tumors.
Contra-Indications:
Known hypersensitivity. Bone marrow aplasia and myelosuppression (platelets below 100,000/mm3 and leukocytes below 4000/mm3), particularly in patients with previous chemotherapy and/or radiotherapy. Acute hemorrhagic cystitis. Infections, including urinary tract infections or acute urothelial toxicity. Lower urinary tract outflow obstructions. Renal impairment, hepatic impairment, pregnancy and breastfeeding.
Special Precautions:
Ifoxan is administered concurrently with Mesna (2-mercaptoethanesulfonic acid sodium salt). In laboratory tests, ifosfamide has been shown to be mutagenic, teratogenic and carcinogenic, and there is a risk of drug-induced neoplasia following long-term treatment. Pregnancy and lactation. Before the initiation of treatment, it is necessary to clear the urinary passages, control any infections and correct any electrolyte imbalance. Regular monitoring of renal function, leucocyte, platelet and erythrocyte counts should be carried out at regular intervals. Patients with cerebral symptoms and brain metastases. Males and females of reproductive age should use contraceptive measures during, and for at least 6 months after, completion of treatment. The carbohydrate metabolism of diabetics should be checked regularly.
Side Effects:
Urothelial toxicity, hemorrhagic cystitis, granular casts in the urinary sediment, Fanconi's syndrome, nausea, vomiting, stomatitis, diarrhea, anorexia, constipation, marrow toxicity, encephalopathy manifested by confusion and lethargy, alopecia, reversible changes in liver function. See prescribing information for full details.
Drug Interactions:
N/A